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ABSTRACT 
Objectives: The primary objective of this study was to compare a traditional green KTP laser to a new 
investigational yellow laser (PhotoLase) in the treatment of facial telangiectasia in terms of the treatment 
outcomes. The secondary objective was to assess the functionality and reliability of the PhotoLase system from 
the perspective of the user.  
Study Design/Methods: The study was a randomized split-face double-blinded study that compared the treatment 
efficacy of the 532-nm KTP laser and the investigational 585-nm PhotoLase laser. One or two treatments were 
given based on the response of the first treatment. The improvement of telangiectasia was graded according to a 
7-point Telangiectasia Grading Scale (TGS) by the subjects and blinded physicians. The subjects assessed the 
amount of pain during the treatments using Visual Analogue Scale (VAS), and evaluated adverse effects 2–3 days 
after the treatment(s) using a self-assessment form.  
Results: At least 50% improvement was seen in 15/18 subjects after the first PhotoLase treatment, and a similar 
result was observed for KTP, as assessed by the blinded physicians (p=0.29). In the subjects’ assessment, 7/18 
subjects had at least 50% improvement after the first PhotoLase treatment, whereas at least 50% improvement 
was observed for 10/18 subjects in the KTP side, the difference being significant (p=0.008). The amount of pain 
was higher with PhotoLase compared to KTP (67.7 vs. 34.6, p<0.001). There was no difference in the frequency 
of erythema, crusting or purpura between the devices, but more blistering and less edema were seen after 
PhotoLase treatment (p<0.05). Treatment with PhotoLase was evaluated to be 4.7-fold faster than with KTP and 
the PhotoLase system was more compact, narrower, lighter and easier to carry than KTP. 
Conclusions: The investigational PhotoLase laser enables significantly faster treatments, but the process is 
somewhat more painful than with KTP, otherwise providing a similar clinical outcome in the treatment of facial 
telangiectasia. 
 
Keywords: Telangiectasia; KTP laser; green laser; yellow laser; semiconductor disk laser technology; 
comparative study  
 
INTRODUCTION 
Millions of people worldwide are affected by facial telangiectases, small dilated blood vessels with diameters 
between 0.1 to 1.0 mm.  Predisposing conditions include rosacea, photodamage, topical steroid use and genetic 
factors. Discomfort and psychological distress drive patients to seek help, and telangiectasia treatments are among 
the most common dermatological laser procedures.1,2 Treatment of superficial vascular lesions is based on 
selective photothermolysis, where the target chromophore is the intravascular oxyhaemoglobin in red blood cells. 
Absorption of laser light heats the chromophore leading to vessel wall damage.  Several lasers are used for 
vascular indications, but the standard lasers are yellow pulsed dye laser (585- or 595-nm) and green potassium-
titanyl-phosphate (KTP) laser (532-nm), because their wavelengths are close to the α and β absorption peaks (542 
and 577 nm) of oxyhaemoglobin.3 
The original PDL (577-nm) had a short pulse duration of 0.3 ms, causing frequently post-operative purpura. 
Modern PDLs, such as CynergyTM (Cynosure) and VBeam® (Syneron Candela) operate at wavelengths of 585  
and 595 nm, respectively, and have micropulse mode and adjustable pulse durations up to 40 ms for less purpura.2 
Spot sizes in CynergyTM and VBeam® range from 3 to 12 mm. Currently available KTP devices have adjustable 
pulse durations from 0.05 to 2000 ms and spot sizes from 0.2 to 12 mm. One KTP system, Aura XP (Laserscope), 
can be equipped with a SmartScan scanner (Laserscope). 
The safety and efficacy of PDL and KTP have been demonstrated in numerous studies, and both are suggested 
as first line treatments for facial telangiectases by the European Society for Laser Dermatology. At least 50–90% 
improvement can be expected after 1–3 treatments.3 For facial capillary malformations, PDL is still the gold 
standard therapy4, but modern large spot size KTPs seem also effective and can be considered first line regimen.5,6 
The advantage of the yellow PDL compared to the green KTP is the longer emission wavelength, enabling 
deeper penetration and treatment of larger vessels. In addition, oxyhaemoglobin has higher absorption for yellow 
than for green wavelengths. Yellow wavelengths also have lower melanin absorption, allowing treatment of darker 
skin phototypes with lower risk of epidermal damage.2 
However, the yellow PDL has some intrinsic disadvantages such as large size and high annual maintenance 
costs. To address the needs of the dermatologic community a novel laser technology, namely optically pumped 
semiconductor disk laser (SDL), has emerged to provide a compact and cost-effective alternative for a yellow 
laser source. SDLs, also known as VECSELs (vertical external-cavity surface-emitting lasers), are recognized for 
their power scaling abilities, transverse mode control and the ability to tailor the emission wavelength according 
to specific application needs.7,8 With the addition of wavelength selective components and suitable laser cavity 
configurations, SDLs can also be designed to emit narrow linewidth9 and have a wavelength tuning range up to 
tens of nanometers.10 Light pulses down to a few hundred nanometers can be easily achieved by directly 
modulating the pump laser of an SDL.11 Another pulsing method, possibly more attractive for medical 
applications, is to use a continuous wave SDL as a source and guide it through a handheld scanning device capable 
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of producing different pulse lengths and treatment patterns by moving the laser beam to a different spot. In this 
case the pulse duration is limited by the mechanical capability rather than by the intrinsic modulation features of 
the semiconductor, which are much faster.    
The primary objective of this pilot study was to compare the efficacy of a yellow laser system based on SDL 
technology to the traditional green KTP laser in the treatment of facial telangiectasia. This included comparing 
the treatment outcome and the adverse effects caused by the treatment. The secondary objective was to assess the 
functionality of the new yellow laser from the point of view of the treating investigators. 
 
MATERIALS AND METHODS 
 
Study Design 
The study was a split-face comparative double-blinded study without a separate control group. It was designed 
to enable a comparison between a traditional green laser and an investigational yellow laser. The split-face design 
eliminated individual biases and the randomization eliminated possible small variations in the symmetry of the 
telangiectases on the face. The double-blinded assessment eliminated subjective and objective biases of the 
investigators and the subjects. The protocol was approved by the Ethics Committee of Tampere University 
Hospital (Reg. No. R17111). The protocol followed the principles of the Declaration of Helsinki and its 
amendments. 
 
Devices 
The study employed two different laser systems: the traditional green KTP laser (Aura XP, Laserscope) and 
the investigational yellow laser called PhotoLase. The KTP laser emits 532-nm radiation up to 15 W, and was 
equipped with a Laserscope SmartScan scanner, which delivered 127 spots with a diameter of 1.0 mm, forming a 
hexagon pattern and covering an area of ~1.1 cm2 in 17.5 seconds. 
The PhotoLase laser (Fig. 1a) was developed at the Optoelectronics Research Centre (ORC), Tampere 
University of Technology in collaboration with the French National Institute of Health and Medical Research 
(INSERM). It emits 585-nm yellow radiation up to 8 W in continuous wave operation, delivered via a multimode 
optical fiber with a diameter of 200 µm. The device was equipped with a MedArt scanner (Fig. 1b) capable of 
delivering the laser light in different patterns (single spot, line, square, and hexagon). One scan covered an area 
of ~1.0 cm2 in less than a second and included 37 spots with a diameter of 1.4 mm. The pulse duration was 
adjustable in the range 10–100 ms. Only the hexagon shape (Fig. 1c) was used to enable a more accurate 
comparison of the two laser systems. The pulse duration was fixed to 25 ms based on pre-clinical tests indicating 
good clinical end-point. A detailed description of the system can be found in Kantola et al. 2019 (in press).   
The study also employed a Canfield Visia Imaging System to assess the effectiveness of the laser treatments. 
The imaging system produces high quality multi-spectral images with standardized lighting and facial positioning.  
 
Subject inclusion and exclusion criteria  
Finnish speaking volunteering adults with symmetrical facial telangiectasia, and a Fitzpatrick’s skin phototype 
I–IV, were included in the study. Exclusion criteria were unbalanced chronic disease, pregnancy, lactation, 
haemophilic condition, being under guardianship, alcohol or drug abuse and significant tanning less than 6 weeks 
prior to the study. All volunteers gave their informed consent. 
 
Treatment Protocol 
The subjects were randomized to receive KTP treatment on one side of the face and PhotoLase on the 
contralateral side. The randomization was performed in blocks of two using a web-based validated program 
(Research Randomizer). The investigators T.K. and A.K. randomized and enrolled all the participants. One to two 
treatments were performed at 1- to 2-month intervals depending on the recommendation of the investigators and 
preferences of the subjects. Prior to the first treatment, the investigators assessed each subject and categorized the 
severity of their telangiectasia into mild, moderate or severe (Fig. 2).  
Treatment parameters were selected to achieve the same clinical end-point of vessel disappearance or clot 
formation within the vessel. Double passes were used when needed. KTP settings were 20–30 J/cm2 at 10-ms 
pulse duration and the PhotoLase settings were 5.6–8.1 J/cm2 at 25-ms pulse duration. No topical anesthesia or 
cooling was used. 
 
Efficacy Assessments 
The primary endpoint of this study was the 7-point Telangiectasia Grading Scale13, which was assessed by the 
subjects and the blinded investigators (T.K. and A.K.). The TGS is scored: -1 = condition worsened; 0 = no 
change; 1 = some improvement (<25%); 2 = intermediate improvement (25–50%), 3 = significant improvement 
(50–75%); 4 = very significant improvement (>75%); 5 = complete resolution of telangiectasia. The investigators 
assessed the TGS using the Visia images taken prior and 1–2 months after the treatment(s). The assessment was 
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performed as a consensus assessment by the investigators T.K. and A.K. Even though T.K. and A.K. also 
performed the treatments, the efficacy assessments can be regarded blinded, since the Visia images did not show 
information about which device was used in either side of the face. In addition, the subjects gave their own best 
assessment of the clinical outcome using a mirror. 
 
Safety Assessments 
Assessment of adverse effects was conducted 48–72 hours after the treatment(s) through a self-assessment 
form given to the subjects. Visual Analogue Scale (VAS, 0–100) was used for pain and a 4-point scale (0=absent, 
1=mild, 2=moderate, 3=severe) for erythema, edema, crusting, purpura and blisters.  
 
Sample Size Calculation 
The sample size calculation assumes, that a clinically important difference, as measured by a 7-point 
Telangiectasia Grading Scale (-1–5), is 2. With an alpha error of 0.05, power of 0.80 and a sigma value of 2, we 
arrived at a sample size of 16 with a sample size calculator comparing two independent samples13. Assuming that 
there will be a few dropouts during the study, a sample size of 20–30 subjects is warranted. 
 
Statistical Analysis 
Statistical comparisons between the KTP and PhotoLase treatments were made using the McNemar test, Wilcoxon 
signed ranks test and permutation test with exact p-values. Stata 15.1 (StataCorp LP; College Station, Texas, 
USA) statistical package was used for the analysis. 
 
RESULTS 
 
General 
Twenty-four subjects participated and completed the study. Six subjects were excluded from the analysis, 
since their telangiectases were not assessable using the Visia images. The mean age of the subjects was 48 years 
(range 27–63 years), sixteen (89%) females and two (11%) males. Nine subjects received KTP on the left cheek 
and PhotoLase on the right cheek, and nine subjects vice versa. Five subjects (28%) received a single treatment 
and thirteen subjects (72%) received two treatments. The Fitzpatrick’s skin phototypes were I, II or III in 6/8/4 
subjects, respectively. The baseline telangiectasia grades were I, II, or III in 4/9/5 subjects, respectively, and the 
grades were symmetrical in all of the subjects. 
 
Safety  
The amount of pain, as measured using VAS, was higher with PhotoLase when compared to KTP, 67.7 (SD 22.9) 
vs. 34.6 (SD 16.9), respectively. There was no difference in the frequency of erythema, crusting or purpura 
between KTP and PhotoLase, as assessed using a 0–3 scale, 2–3 days after the treatments. More blistering and 
less edema were seen after PhotoLase treatment (p < 0.05, Table 1). A small superficial atrophic scar was noted 
in two subjects on the PhotoLase side. 
 
Efficacy 
In the blinded investigators’ assessment, fifteen subjects (83%) had a TGS value of 3 or larger, indicating at least 
50% improvement after the first PhotoLase treatment, and a similar result was observed for KTP (p=0.29). In the 
subjects’ assessment, seven subjects (39%) had at least 50% improvement after the first PhotoLase treatment, 
whereas at least 50% improvement was observed for ten subjects (56%) in the KTP side, the difference being 
significant (p=0.008).  
The potential benefit of the optional second treatment was also assessed by the subjects and the blinded 
investigators. Based on the subjects’ assessment, 11/13 benefited from the second KTP treatment, and 10/13 from 
the second PhotoLase treatment. The difference between the devices was insignificant (p=0.54). Based on the 
blinded investigators’ consensus assessment, 9/13 subjects benefited from the second KTP treatment, and 8/13 
from the second PhotoLase treatment. The difference between the devices was insignificant (p=0.81). 
Figs. 3 and 4 show the before and after Visia images of a female subject with moderate telangiectasia. 
Photographs were taken before and after the treatments. The left side was treated with KTP and the right side with 
PhotoLase. In this case, the improvement in TGS was 4 on the KTP side and 3 on the Photolase side after the first 
treatment and 4 on both sides after the second treatment. 
 
Functionality of the investigational device 
The secondary objective of the study was to assess the functionality of the investigational device. The 
evaluation was performed by the investigators (T.K. and A.K.) based on their user-experience during the study. 
The most obvious difference in functionality was observed in the scanning speeds of the scanners, 17.5 seconds 
per 1.1 cm2 for the SmartScan scanner (KTP) and less than one second per 1.0 cm2 for the MedArt scanner 
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(PhotoLase). Assuming a mean of three seconds between the scans, this yields a 4.7-fold difference in treatment 
speed favouring PhotoLase. The SmartScan scanner was also larger, bulkier and heavier. The button that was 
pressed to initiate the scanning was integrated to the SmartScan scanner, but the MedArt scanner was used with 
a foot pedal. The investigators favored the hand-button for easier administration of the pulses. The investigational 
device PhotoLase appeared to be more compact, narrower, lighter and easier to carry compared to the KTP laser. 
Both laser systems were stable during the trial period and no malfunctions were noted. 
 
DISCUSSION 
To our knowledge, this is the first head-to-head study to compare a 585-nm yellow SDL to a traditional 532-
nm green KTP laser in the treatment of facial telangiectasia. We were able to recruit the desired number of subjects 
with full compliance throughout the study period, and both laser systems were shown similarly effective. 
Recently Kapicioglu et al. (2018) reported a non-controlled case series using a 577-nm yellow SDL for the 
treatment of erythematotelangiectatic rosacea, facial erythema and facial telangiectasia. They achieved over 80% 
cure rate for facial erythema and telangiectasia in 76.6% of subjects after first treatment, whereas we achieved 
over 50% cure rate in 83.3% of cheeks treated with PhotoLase or KTP. Our parameters for KTP were 20–30 J/cm2 
at 10-ms pulse duration and for PhotoLase 5.6–8.1 J/cm2 at 25-ms pulse duration. In comparison, Kapiciogly et 
al. used 16–22 J/cm2 fluences with the 577-nm laser. There are probably two main reasons for the cure rate 
difference. Firstly, our trial was conducted in private sector, where typically milder presentations of telangiectasia 
are treated, compared to hospital conditions. Only 28% of our subjects had severe telangiectasia. Secondly, we 
chose not to use topical anesthesia or cooling to prevent possible vasoconstriction in the treatment area, which 
resulted in limitation to use higher PhotoLase fluences due to pain. 
Another split-face study by Uebelhoer et al. (2007) compared KTP (Gemini, Laserscope) and 595-nm PDL 
(VBeam®) for facial telangiectases. The PDL settings were a 10-mm spot, a fluence of 7.5 J/cm2, a 10-ms pulse 
duration, optional pulse stacking, and dynamic nitrogen cooling spray. The KTP settings were mostly 10 J/cm2 at 
18 ms and 9 J/cm2 at 23 ms with 5- and 10-mm spot sizes, respectively, and a sapphire contact cooling. The 
percentage of improvement was 62% with KTP, and 49% with PDL after the first treatment, being slightly lower 
than cure rates in our study. Tanghetti et al. (2012) used a 595-nm PDL (V-Star®, Cynosure) for facial 
telangiectases with Zimmer air cooling and could use fluences as high as 8.1–14.5 J/cm2 with 10- and 40-ms pulse 
durations. In their study, about 80% of subjects reached a 50% or higher cure rate with 1–2 treatments, a result 
that we reported after the first treatment with PhotoLase. 
Like the yellow SDLs, modern large spot size KTPs can challenge the gold standard role of PDLs, as shown 
by Uebelhoer et al. More recently, Kwiek et al. (2017, 2018) showed the efficacy of large spot size KTP (ExcelV®, 
Cutera) in patients with facial capillary malformations. The settings were a 5- to 10-mm spot size, a fluence of 8–
11.5 J/cm2 and pulse duration 4 to 9 ms. An integrated sapphire glass contact cooling was used. The median 
improvement was 70.4% after a mean of 7.1 treatments in previously non-treated patients5, and 59.1% after a 
mean of 6.2 treatments in previously treated patients6. 
No serious side effects were reported during the present study. More blistering, but less edema was observed 
for the PhotoLase system compared to KTP. A small superficial atrophic scar resulting from a blister was noted 
in the PhotoLase side in two subjects, which is an unwanted adverse effect that we want to eliminate in the future.  
Instead of a fixed pulse duration, we will tailor the pulse duration for the vessel caliber in the future. In addition, 
epidermal cooling will be included to prevent epidermal damage and to optimize treatment parameters. We are 
planning to use either an updated scanner with an integrated contact cooling, or air cooling in our future trials. 
The 4.7-fold faster treatment time using the MedArt scanner can be considered a major benefit compared to 
SmartScan scanner. The power reserve of PhotoLase also makes it possible to increase the scanning area of one 
illumination sequence while still applying sufficient fluence on the treatment area. This would further reduce the 
time of treatment, especially for larger treatment areas. We acknowledge that the present study would be stronger, 
if the PhotoLase system was compared to a modern PDL or large spot size KTP. The functionality and speed of 
modern devices are on a different level than that of Aura XP with SmartScan. Newer KTP devices with large spot 
size can also treat telangiectases with lower fluencies due to deeper penetration and even distribution of energy, 
reducing the cooling effect of blood flow.6 On the other hand, we still consider it fair to compare the clinical 
outcome of the present devices, since the scanning patterns were similar and the spots sizes were close to each 
other in terms of diameter. 
The strengths of the present study are the randomized split-face design, high-quality Visia images and 
excellent subject compliance. Some discrepancy can be seen in the subjects’ TGS assessment compared to blinded 
investigators’ consensus assessment. We believe that such a difference resulted from the insensitivity of the TGS 
assessment tool, which has relatively large 25% grading steps. Subjects might easily give different curing scores, 
if they notice even a slight difference in the erythema between face sides. Experienced clinicians, then again, will 
not let too small differences distract the overall assessment. Also, the subjects’ assessment was based on their 
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memory, whereas the blinded investigators had high-quality standard and erythema-weighted images to compare 
the results very systematically. 
 
CONCLUSION 
To conclude, we demonstrated non-inferiority of the novel yellow semiconductor disk laser, PhotoLase, in the 
treatment of facial telangiectasia compared to the traditional green KTP laser. A major benefit of the PhotoLase 
is the significant decrease of treatment time, which could be further decreased by enlarging the scanning area for 
single illumination. The PhotoLase system can also be considered more user-friendly in the present setting. 
However, larger studies with optimized cooling, laser parameter tailoring, and comparison to modern PDL or 
KTP devices are warranted in the future. 
ACKNOWLEDGMENTS 
The authors would like to thank M. Sc. (Tech) Iiro Leino (TUT) and Pascal Deleporte (INSERM) for their 
contributions in the design and assembly of the investigational device PhotoLase. This work was financially 
supported by the Finnish Funding Agency for Innovation (TEKES) as part of FidiPro project Photolase 
(#40152/14). E. Kantola would also like to acknowledge Antti and Jenny Wihuri Foundation for their support.  
 
TABLES AND FIGURES 
Table 1. The frequency of treatment reactions of the first treatment with KTP and PhotoLase. The intensity of 
the reactions was scaled: 0=absent, 1=mild, 2=moderate, 3=severe. 
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Adverse effect Treatment 
reactions 2-3 
days after KTP 
treatment (%) 
Treatment 
reactions 2-3 days 
after PhotoLase 
treatment (%) 
P-value 
Erythema   0.87 
   0 1 (6) 2 (11)  
   1 7 (39) 7 (39)  
   2 8 (44) 6 (33)  
   3 2 (11) 3 (17)  
Crusting   0.55 
   0 11 (61) 9 (50)  
   1 4 (22) 5 (28)  
   2 3 (17) 3 (17)  
   3 0 (0) 1 (6)  
Edema   0.007 
   0 2 (11) 3 (17)  
   1 1 (6) 7 (39)  
   2 5 (28) 6 (33)  
   3 10 (56) 2 (11)  
Purpura   0.12 
   0 11 (61) 14 (78)  
   1 3 (17) 3 (17)  
   2 1 (6) 1 (6)  
   3 1 (6) 0 (0)  
Blistering   0.023 
   0 15 (83) 10 (56)  
   1 3 (17) 3 (17)  
   2 0 (0) 3 (17)  
   3 0 (0) 2 (11)  
P-values calculated with Wilcoxon signed ranks test.  
 
